Sartorius Stedim stock sits 2.76 percent below its yearly high ahead of results

Published on 10/19/2026 at 09:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius Stedim stock costs EUR 214.90 on October 19, 2026, below EUR 221.00. Results are due October 22, with sales growth guided at 6 to 10 percent.

Upcoming results and guidance

Sartorius Stedim Biotech is scheduled to present nine-month 2026 results on October 22, 2026.
Fiscal year 2026 sales guidance calls for 6 to 10 percent growth in constant currencies.
Sartorius Stedim stock trades at EUR 214.90 at 9:18 a.m. CEST at Lang & Schwarz on October 19, 2026.

Extreme Nahaufnahme einer transparenten Filtermembran mit Flüssigkeitstropfen — Sartorius Stedim Biotech Makroaufnahme einer transparenten Filtermembran mit feinen Flüssigkeitstropfen, ISIN FR0013154002, Illustration mit AI erstellt.

Sartorius Stedim Biotech (ISIN FR0013154002) was at EUR 214.90 at Lang & Schwarz on October 19, 2026, at 9:18 a.m. CEST. The stock stood 2.76 percent below the EUR 221.00 52-week high cited in a German market factsheet dated October 16, 2026, while the company prepares to publish nine-month results on October 22.

Results due on October 22

The next scheduled event is the release of Sartorius Stedim Biotech's results for the nine months ended September 30, 2026. The investor-relations page lists a conference call for October 22, 2026, at 1 p.m. CEST, giving investors a defined date for the next operating update, according to Sartorius Stedim Biotech.

The market is entering that report with a clear comparison point. finanzen.ch reported on October 7, 2026, that three analysts expected third-quarter revenue of EUR 755.6 million, up 7.07 percent from EUR 705.7 million a year earlier. Their average earnings-per-share estimate was EUR 1.19, compared with EUR 0.66 in the prior-year quarter.

What does guidance imply for margins?

Management's fiscal year 2026 outlook calls for sales revenue growth of 6 to 10 percent in constant currencies and an underlying EBITDA margin slightly above 31 percent, as stated on the company's investor-relations page. That margin target is higher than the 30.8 percent underlying EBITDA margin reported for fiscal year 2025, so the upcoming figures will test both demand and operating leverage.

Which dates matter next?

The October 22 results and conference call are the next dated company milestones. The latest analyst action in the research window came from RBC Capital Markets on October 6, 2026: the bank kept its Outperform rating and a EUR 210.00 price target after updating its model for US tariff refunds, the MatTek acquisition and currency effects, according to finanzen.at.

Stock stays below yearly high

The EUR 214.90 quote is 2.76 percent below the EUR 221.00 52-week high and remains above the EUR 149.60 low listed in the October 16 factsheet from Volksbank eG, Wolfenbuettel. The forthcoming report therefore has a defined valuation backdrop and a concrete profitability benchmark.

Sartorius Stedim Biotech was trading at EUR 214.90 at Lang & Schwarz on October 19, 2026, at 9:18 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Sartorius Stedim stock.